<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00110214</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02814</org_study_id>
    <secondary_id>NCI-2012-02814</secondary_id>
    <secondary_id>CDR0000427290</secondary_id>
    <secondary_id>CALGB-90401</secondary_id>
    <secondary_id>CALGB-90401</secondary_id>
    <secondary_id>P30CA014236</secondary_id>
    <secondary_id>U10CA031946</secondary_id>
    <nct_id>NCT00110214</nct_id>
  </id_info>
  <brief_title>Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy</brief_title>
  <official_title>A Randomized Double-Blinded Placebo Controlled Phase III Trial Comparing Doctaxel and Prednisone With and Without Bevacizumab (IND #7921, NSC #704865) in Men With Hormone Refractory Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This randomized phase III trial is studying docetaxel, prednisone, and bevacizumab to see how
      well they work compared to docetaxel and prednisone in treating patients with prostate cancer
      that did not respond to hormone therapy. Drugs used in chemotherapy, such as docetaxel and
      prednisone, work in different ways to stop the growth of tumor cells, either by killing the
      cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can
      block tumor growth in different ways. Some block the ability of tumor cells to grow and
      spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
      Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. It
      is not yet known whether docetaxel, prednisone, and bevacizumab are more effective than
      docetaxel and prednisone in treating prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine if the addition of bevacizumab to docetaxel and prednisone increases overall
      survival compared to docetaxel and prednisone alone in patients with HRPC.

      SECONDARY OBJECTIVES:

      I. To compare the progression-free survival of these two regimens in patients with HRPC.

      II. To compare the two regimens on the proportion of patients who experience a 50%
      post-therapy PSA decline from baseline.

      III. To compare the two regimens with respect to the proportion of patients who experience
      grade 3 or higher toxicities.

      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients
      are stratified according to predicted 24-month survival probability (&lt; 10% vs 10-29.9% vs ≥
      30%), age (&lt; 65 years vs ≥ 65 years), and prior history of arterial events (i.e., cardiac
      ischemia/infarction, CNS cerebrovascular ischemia, peripheral arterial ischemia, or CNS
      hemorrhage) (yes vs no). Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive docetaxel IV over 1 hour and placebo IV over 30-90 minutes on day 1.
      Patients also receive oral prednisone once daily on days 1-21.

      ARM II: Patients receive docetaxel and prednisone as in arm I. Patients also receive
      bevacizumab IV over 30-90 minutes on day 1.

      In both arms, courses repeat every 21 days for up to 2 years in the absence of disease
      progression or unacceptable toxicity.

      After completion of study treatment, patients are followed periodically for up to 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Duration of study (up to 5 years)</time_frame>
    <description>Overall Survival (OS) was measured from the date of randomization to date of death due to any cause. OS was estimated using the Kaplan Meier method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Who Experienced at Least a 50% Post-therapy PSA (Prostate-Specific Antigen) Decline</measure>
    <time_frame>Duration of study (up to 5 years)</time_frame>
    <description>PSA decline will be reported on all patients and will be defined as a decrease in PSA value by &gt;= 50% for two successive evaluations at least 4 weeks apart. The reference PSA value for these declines should be measured within 2 weeks before starting therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Duration of study (up to 5 years)</time_frame>
    <description>PFS was defined as the data of randomization to date of progression or death due to any cause, whichever occurs first. PFS was estimated using the Kaplan Meier method.
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Who Experience (Maximum) Grade 3 or Higher Toxicities</measure>
    <time_frame>During treatment (up to 2 years)</time_frame>
    <description>The National Cancer Institute (NCI) Criteria for Adverse Events(CTCAE) Version 3.0 was used to evaluate toxicity. These events were considered at least possibly related to treatment.
Grade 1: mild; Grade 2: moderate; Grade 3: Severe; Grade 4: Life Threatening; Grade 5: Death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1050</enrollment>
  <condition>Adenocarcinoma of the Prostate</condition>
  <condition>Hormone-resistant Prostate Cancer</condition>
  <condition>Recurrent Prostate Cancer</condition>
  <condition>Stage IV Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive docetaxel IV over 1 hour and placebo IV over 30-90 minutes on day 1. Patients also receive oral prednisone once daily on days 1-21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive docetaxel and prednisone as in arm I. Patients also receive bevacizumab IV over 30-90 minutes on day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>RP 56976</other_name>
    <other_name>Taxotere</other_name>
    <other_name>TXT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>DeCortin</other_name>
    <other_name>Deltra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>anti-VEGF humanized monoclonal antibody</other_name>
    <other_name>anti-VEGF monoclonal antibody</other_name>
    <other_name>Avastin</other_name>
    <other_name>rhuMAb VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically documented adenocarcinoma of the prostate with
             progressive systemic (clinically metastatic disease documented on bone, CT or MRI
             scan) disease despite castrate levels of testosterone due to orchiectomy or LHRH
             agonist; castrate levels of testosterone must be maintained

          -  All eligible patients must have a Gleason sum based on biopsy or TURP at the time of
             registration

          -  At the time of enrollment, patients must have evidence of progressive metastatic
             disease, either:

               -  Measurable disease with any level of serum PSA OR

               -  Non-measurable disease with PSA ≥ 5 ng/ml; patients with PSA ≥ 5 ng/ml only and
                  no other radiographic evidence of metastatic prostate cancer are not eligible

          -  Definition of Measurable Disease/Target Lesions:

               -  Any lesion that can be accurately measured in at least one dimension (longest
                  diameter to be recorded) as ≥ 20 mm with conventional techniques: 1) physical
                  exam for clinically palpable lymph nodes and superficial skin lesions, 2) chest
                  X-ray for clearly defined lung lesions surrounded by aerated lung OR those
                  lesions measured as ≥ 10 mm with a spiral CT or MRI scan

               -  Measurable lesions (up to a maximum of 10 in number) representative of all organs
                  involved to be identified as target lesions; the sum of the longest diameters
                  (LD) for all target lesions will be calculated and reported as baseline sum LD

                    -  If measurable disease is confined to a solitary lesion and is not consistent
                       with prostate cancer, then its neoplastic nature must be confirmed by
                       histology

                    -  Ultrasound may not be used to measure tumor lesions that are not easily
                       accessible clinically

          -  Definition of Non-measurable Disease/Non-target Lesions:

               -  Non-target lesions include all other lesions not included in above, including
                  small lesions with longest diameter &lt; 20 mm with conventional techniques or &lt; 10
                  mm with spiral CT scan and truly non-measurable lesions, which include:

                    -  Bone lesions

                    -  Pleural or pericardial effusions, ascites

                    -  CNS lesions, leptomeningeal disease

                    -  Irradiated lesions, unless progression documented after RT

          -  Patients must have demonstrated evidence of progressive disease since the most recent
             change in therapy; progressive disease is defined as any one of the following
             (measurable disease, bone scan, or PSA progression):

               -  Measurable Disease Progression: Objective evidence of increase &gt; 20% in the sum
                  of the longest diameters (LD) of target lesions from the time of maximal
                  regression or the appearance of one or more new lesions

               -  Bone Scan Progression: Appearance of one or more new lesions on bone scan
                  attributable to prostate cancer along with a PSA ≥ 5 ng/ml will constitute
                  progression

               -  PSA Progression: An elevated PSA (≥ 5 ng/mL) which has risen serially on at least
                  two occasions after the discontinuation of antiandrogen therapy, each at least
                  one week apart; if the confirmatory PSA (#3) value is less than screening PSA
                  (#2) value, then an additional test for rising PSA (#4) will be required to
                  document progression

                    -  The reference PSA value (#1) must be measured at the time of the
                       discontinuation of antiandrogen therapy; and at least 2 PSA measurements
                       must be made following the end of antiandrogen therapy and prior to
                       registration

                    -  (For the purposes of the nomogram calculator, the last PSA value recorded
                       prior to the initiation of treatment will be considered the baseline PSA)

          -  Progression despite standard androgen deprivation therapy (i.e., LHRH agonist and/or
             orchiectomy)

          -  All antiandrogens (e.g., flutamide, megestrol acetate [even if taken for hot flashes],
             bicalutamide and nilutamide) of any dose must be discontinued at least 4 weeks prior
             to registration; if improvement following antiandrogen withdrawal is noted,
             progression must be established using the criteria above

               -  Primary testicular androgen suppression (e.g., with an LHRH agonist) should not
                  be discontinued

          -  At least 4 weeks since any other hormonal therapy, including ketoconazole and
             aminoglutethimide; the only exception to this time frame is that 5α-reductase
             inhibitors (e.g., finasteride, dutasteride) may be discontinued any time prior to
             registration

          -  No prior cytotoxic chemotherapy, including estramustine or suramin

          -  No prior anti-angiogenesis agents, including thalidomide and bevacizumab

          -  ≥ 4 weeks since major surgery and fully recovered

          -  ≥ 4 weeks since any prior radiation (including palliative) and fully recovered

          -  ≥ 8 weeks since the last dose of Strontium-89 or Samarium

          -  Patients receiving a bisphosphonate must be on a stable dose and must have started the
             bisphosphonate ≥ 4 weeks prior to initiating protocol treatment. Patients do not have
             to be on a bisphosphonate to qualify for the study; patients may initiate
             bisphosphonate therapy after completion of Cycle 1, if clinically indicated

               -  Patients enrolled on CALGB 90202 who have documented disease progression and have
                  received at least 4 weeks of open label zoledronic acid treatment, are eligible
                  for this study.

          -  No known brain metastases (brain imaging (MRI/CT) is not required)

          -  No current congestive heart failure (New York Heart Association Class II, III or IV)

          -  Patients with history of hypertension must be well controlled (&lt; 160/90) on a regimen
             of anti-hypertensive therapy

          -  Patients on full-dose anticoagulants must be on a stable dose of warfarin and have an
             in-range INR (usually between 2 and 3) or be on a stable dose of LMW heparin; patients
             receiving anti-platelet agents are also eligible; in addition, patients who are on
             daily prophylactic aspirin or anticoagulation for atrial fibrillation are eligible

          -  No significant history of bleeding events or GI perforation

               -  Patients with a history of significant bleeding episodes (e.g., hemoptysis, upper
                  or lower GI bleeding) within 6 months of registration are not eligible

               -  Patients with a history of GI perforation within 12 months of registration are
                  not eligible.

          -  No recent (within 12 months) arterial thrombotic events, including transient ischemic
             attack (TIA), cerebrovascular accident (CVA), unstable angina or angina requiring
             surgical or medical intervention in the past 12 months, or myocardial infarction (MI);
             patients with clinically significant peripheral artery disease (i.e., claudication on
             less than one block) or any other arterial thrombotic event are also ineligible

          -  No serious or non-healing wound, ulcer or bone fracture

          -  No peripheral neuropathy ≥ grade 2

          -  Patients with known hypersensitivity to Chinese hamster ovary cell products or other
             recombinant human antibodies are not eligible

          -  PC-Spes, Saw Palmetto, and St. John's Wort must be discontinued before registration;
             the discontinuation of other herbal medications and food supplements is strongly
             encouraged; patients may continue on daily vitamins and calcium supplements

          -  ECOG performance status: 0-2

          -  ANC ≥ 1500/μL

          -  Platelet count ≥ 100,000/μL

          -  Creatinine ≤ 1.5 x upper limits of normal

          -  Bilirubin ≤ 1.5 x upper limits of normal

               -  For patients with Gilbert's Disease, ≤ 2.5 X ULN is allowed

          -  AST ≤ 1.5 x upper limits of normal

          -  PSA ≥ 5 ng/mL (if non-measurable disease)

          -  Urine protein to creatinine ratio &lt; 1.0
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Kelly</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer and Leukemia Group B</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer and Leukemia Group B</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
  </removed_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2005</study_first_submitted>
  <study_first_submitted_qc>May 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2005</study_first_posted>
  <results_first_submitted>March 7, 2013</results_first_submitted>
  <results_first_submitted_qc>March 7, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 17, 2013</results_first_posted>
  <last_update_submitted>April 21, 2014</last_update_submitted>
  <last_update_submitted_qc>April 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between May 2005 and December 2007, 1,050 participants were recruited and randomized</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Docetaxel + Placebo</title>
          <description>Standard treatment Docetaxel: 75 mg/m2 by IV over 1 hour for 21 days, Prednisone: 5mg orally twice per day Placebo</description>
        </group>
        <group group_id="P2">
          <title>Docetaxel + Bevacizumab</title>
          <description>Std Tx + monoclonal antibody therapy Docetaxel: 75 mg/m2 by IV over 1 hour for 21 days, Prednisone: 5mg orally twice per day Bevacizumab: 15 mg/kg IV every 3 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="526"/>
                <participants group_id="P2" count="524"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="509"/>
                <participants group_id="P2" count="503"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Never started treatment</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression or death</title>
              <participants_list>
                <participants group_id="P1" count="260"/>
                <participants group_id="P2" count="151"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="192"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused further treatment</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other (not specified)</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Docetaxel + Placebo</title>
          <description>Standard treatment Docetaxel: 75 mg/m2 by IV over 1 hour for 21 days, Prednisone: 5mg orally twice per day Placebo</description>
        </group>
        <group group_id="B2">
          <title>Docetaxel + Bevacizumab</title>
          <description>Std Tx + monoclonal antibody therapy Docetaxel: 75 mg/m2 by IV over 1 hour for 21 days, Prednisone: 5mg orally twice per day Bevacizumab: 15 mg/kg IV every 3 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="526"/>
            <count group_id="B2" value="524"/>
            <count group_id="B3" value="1050"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.3" lower_limit="62.4" upper_limit="75.6"/>
                    <measurement group_id="B2" value="68.8" lower_limit="63.0" upper_limit="74.4"/>
                    <measurement group_id="B3" value="69.0" lower_limit="62.7" upper_limit="75.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="174"/>
                    <measurement group_id="B2" value="179"/>
                    <measurement group_id="B3" value="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="352"/>
                    <measurement group_id="B2" value="345"/>
                    <measurement group_id="B3" value="697"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="526"/>
                    <measurement group_id="B2" value="524"/>
                    <measurement group_id="B3" value="1050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="526"/>
                    <measurement group_id="B2" value="524"/>
                    <measurement group_id="B3" value="1050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>24-month predicted survival probability</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;10%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-29.9%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="184"/>
                    <measurement group_id="B2" value="183"/>
                    <measurement group_id="B3" value="367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=30%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="247"/>
                    <measurement group_id="B2" value="247"/>
                    <measurement group_id="B3" value="494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior history of arterial events</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="484"/>
                    <measurement group_id="B2" value="487"/>
                    <measurement group_id="B3" value="971"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Overall Survival (OS) was measured from the date of randomization to date of death due to any cause. OS was estimated using the Kaplan Meier method.</description>
        <time_frame>Duration of study (up to 5 years)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel + Placebo</title>
            <description>Standard treatment Docetaxel: 75 mg/m2 by IV over 1 hour for 21 days, Prednisone: 5mg orally twice per day Placebo</description>
          </group>
          <group group_id="O2">
            <title>Docetaxel + Bevacizumab</title>
            <description>Std Tx + monoclonal antibody therapy Docetaxel: 75 mg/m2 by IV over 1 hour for 21 days, Prednisone: 5mg orally twice per day Bevacizumab: 15 mg/kg IV every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall Survival (OS) was measured from the date of randomization to date of death due to any cause. OS was estimated using the Kaplan Meier method.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="526"/>
                <count group_id="O2" value="524"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" lower_limit="20.0" upper_limit="23.0"/>
                    <measurement group_id="O2" value="22.6" lower_limit="21.1" upper_limit="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Superiority and futility analyses were conducted for the OS end point. The Lan-Demets analog of the Emerson-Fleming sequential boundary was used to maintain the overall significance level of alpha=0.05 while conducting interim analyses on OS. The final analysis was performed when 748 deaths had been observed. An intention-to-treat approach was used in the analysis for all the clinical end points with the exception of toxicity.</non_inferiority_desc>
            <p_value>0.181</p_value>
            <p_value_desc>The primary analysis was adjusted for the stratification factors (24-mo survival probability as predicted by a validated nomogram (&lt;10%,10%-29.9%,&gt;=30%), age (&lt;65, &gt;=65 years) and prior history of arterial events (yes, no)).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants Who Experienced at Least a 50% Post-therapy PSA (Prostate-Specific Antigen) Decline</title>
        <description>PSA decline will be reported on all patients and will be defined as a decrease in PSA value by &gt;= 50% for two successive evaluations at least 4 weeks apart. The reference PSA value for these declines should be measured within 2 weeks before starting therapy.</description>
        <time_frame>Duration of study (up to 5 years)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel + Placebo</title>
            <description>Standard treatment Docetaxel: 75 mg/m2 by IV over 1 hour for 21 days, Prednisone: 5mg orally twice per day Placebo</description>
          </group>
          <group group_id="O2">
            <title>Docetaxel + Bevacizumab</title>
            <description>Std Tx + monoclonal antibody therapy Docetaxel: 75 mg/m2 by IV over 1 hour for 21 days, Prednisone: 5mg orally twice per day Bevacizumab: 15 mg/kg IV every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants Who Experienced at Least a 50% Post-therapy PSA (Prostate-Specific Antigen) Decline</title>
          <description>PSA decline will be reported on all patients and will be defined as a decrease in PSA value by &gt;= 50% for two successive evaluations at least 4 weeks apart. The reference PSA value for these declines should be measured within 2 weeks before starting therapy.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="526"/>
                <count group_id="O2" value="524"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.9"/>
                    <measurement group_id="O2" value="69.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>PFS was defined as the data of randomization to date of progression or death due to any cause, whichever occurs first. PFS was estimated using the Kaplan Meier method.
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
        <time_frame>Duration of study (up to 5 years)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel + Placebo</title>
            <description>Standard treatment Docetaxel: 75 mg/m2 by IV over 1 hour for 21 days, Prednisone: 5mg orally twice per day Placebo</description>
          </group>
          <group group_id="O2">
            <title>Docetaxel + Bevacizumab</title>
            <description>Std Tx + monoclonal antibody therapy Docetaxel: 75 mg/m2 by IV over 1 hour for 21 days, Prednisone: 5mg orally twice per day Bevacizumab: 15 mg/kg IV every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>PFS was defined as the data of randomization to date of progression or death due to any cause, whichever occurs first. PFS was estimated using the Kaplan Meier method.
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="526"/>
                <count group_id="O2" value="524"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="6.8" upper_limit="8.0"/>
                    <measurement group_id="O2" value="9.9" lower_limit="9.0" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The primary analysis was adjusted for the stratification factors (24-mo survival probability as predicted by a validated nomogram (&lt;10%,10%-29.9%,&gt;=30%), age (&lt;65, &gt;=65 years) and prior history of arterial events (yes, no)).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants Who Experience (Maximum) Grade 3 or Higher Toxicities</title>
        <description>The National Cancer Institute (NCI) Criteria for Adverse Events(CTCAE) Version 3.0 was used to evaluate toxicity. These events were considered at least possibly related to treatment.
Grade 1: mild; Grade 2: moderate; Grade 3: Severe; Grade 4: Life Threatening; Grade 5: Death</description>
        <time_frame>During treatment (up to 2 years)</time_frame>
        <population>Participants who did not received allocated intervention were excluded from toxicity analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel + Placebo</title>
            <description>Standard treatment Docetaxel: 75 mg/m2 by IV over 1 hour for 21 days, Prednisone: 5mg orally twice per day Placebo</description>
          </group>
          <group group_id="O2">
            <title>Docetaxel + Bevacizumab</title>
            <description>Std Tx + monoclonal antibody therapy Docetaxel: 75 mg/m2 by IV over 1 hour for 21 days, Prednisone: 5mg orally twice per day Bevacizumab: 15 mg/kg IV every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants Who Experience (Maximum) Grade 3 or Higher Toxicities</title>
          <description>The National Cancer Institute (NCI) Criteria for Adverse Events(CTCAE) Version 3.0 was used to evaluate toxicity. These events were considered at least possibly related to treatment.
Grade 1: mild; Grade 2: moderate; Grade 3: Severe; Grade 4: Life Threatening; Grade 5: Death</description>
          <population>Participants who did not received allocated intervention were excluded from toxicity analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="505"/>
                <count group_id="O2" value="504"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.2"/>
                    <measurement group_id="O2" value="75.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Participants who did not received allocated intervention were excluded from toxicity analysis</desc>
      <group_list>
        <group group_id="E1">
          <title>Docetaxel + Placebo</title>
          <description>Standard treatment Docetaxel: 75 mg/m2 by IV over 1 hour for 21 days, Prednisone: 5mg orally twice per day Placebo</description>
        </group>
        <group group_id="E2">
          <title>Docetaxel + Bevacizumab</title>
          <description>Std Tx + monoclonal antibody therapy Docetaxel: 75 mg/m2 by IV over 1 hour for 21 days, Prednisone: 5mg orally twice per day Bevacizumab: 15 mg/kg IV every 3 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 6</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="237" subjects_at_risk="505"/>
                <counts group_id="E2" subjects_affected="178" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>DIC (disseminated intravascular coagulation)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="25" subjects_at_risk="505"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="505"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Lymphatics - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmia - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Cardiac General - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="505"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary arrest cause unknown (non-fatal)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Conduction abnormality/atrioventricular heart block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Left ventricular diastolic dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="505"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid function high (hyperthyroidism thyrotoxicosis)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular/Visual - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Vision-blurred vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Watery eye (epiphora tearing)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="505"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Enteritis (inflammation of the small bowel)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Fistula, GI</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="505"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Gastritis (including bile reflux gastritis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Heartburn/dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI</sub_title>
                <counts group_id="E1" events="42" subjects_affected="38" subjects_at_risk="505"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (functional/symptomatic)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="505"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Obstruction GI</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Perforation, GI</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="505"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Ulcer GI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Ulcer, GI</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="505"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death not associated with CTCAE term</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="505"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="46" subjects_affected="39" subjects_at_risk="505"/>
                <counts group_id="E2" events="27" subjects_affected="22" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="47" subjects_affected="43" subjects_at_risk="505"/>
                <counts group_id="E2" events="35" subjects_affected="32" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Injection site reaction/extravasation changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Pain - Other</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="505"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="505"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Necrosis GI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Necrosis, GI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Obstruction, GI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="505"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Colitis, infectious (e.g., Clostridium difficile)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="505"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="41" subjects_affected="35" subjects_at_risk="505"/>
                <counts group_id="E2" events="30" subjects_affected="27" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="505"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="505"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="505"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Opportunistic infection associated with &gt;=Grade 2 Lymphopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism (vascular access-related)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Wound complication non-infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>AST, SGOT(serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Cardiac troponin I (cTnI)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Cardiac troponin T (cTnT)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Coagulation - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Fibrinogen</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>INR (International Normalized Ratio of prothrombin time)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="48" subjects_affected="39" subjects_at_risk="505"/>
                <counts group_id="E2" events="28" subjects_affected="25" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="505"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="79" subjects_affected="67" subjects_at_risk="505"/>
                <counts group_id="E2" events="58" subjects_affected="46" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC) for BMT studies if specified in the protocol.</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>PTT (Partial Thromboplastin Time)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis (metabolic or respiratory)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="505"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Calcium serum-high (hypercalcemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Calcium serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="505"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="32" subjects_affected="27" subjects_at_risk="505"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Glucose serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="505"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Glucose serum-low (hypoglycemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Phosphate serum-low (hypophosphatemia)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="505"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Potassium serum-high (hyperkalemia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Potassium serum-low (hypokalemia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="505"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Sodium serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="505"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="505"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Osteonecrosis (avascular necrosis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Trismus (difficulty, restriction or pain when opening mouth)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia (incoordination)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="505"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Hemorrhage CNS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Neurology - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Neuropathy: motor</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="505"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="505"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="27" subjects_affected="25" subjects_at_risk="505"/>
                <counts group_id="E2" events="24" subjects_affected="19" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Somnolence/depressed level of consciousness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="505"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Speech impairment (e.g., dysphasia or aphasia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Syncope (fainting)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="505"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Mood alteration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Psychosis (hallucinations/delusions)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Fistula, GU</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Hematuria (in the absence of vaginal bleeding)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Hemoglobinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Hemorrhage GU</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="505"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Incontinence, urinary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Obstruction, GU</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Perforation GU</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="26" subjects_affected="22" subjects_at_risk="505"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="505"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Stricture/stenosis (including anastomotic), GU</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Urinary retention (including neurogenic bladder)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult Respiratory Distress Syndrome (ARDS)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Bronchospasm wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="505"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Hemorrhage pulmonary/upper respiratory</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="505"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="505"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Voice changes/dysarthria (e.g. hoarseness loss or alteration in voice laryngitis)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hair loss/alopecia (scalp or body)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="505"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Rash: hand-foot skin reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Skin breakdown/decubitus ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Urticaria (hives welts wheals)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes/flushes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="27" subjects_affected="24" subjects_at_risk="505"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="505"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="505"/>
                <counts group_id="E2" events="31" subjects_affected="28" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Vascular - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 6</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="420" subjects_at_risk="505"/>
                <counts group_id="E2" subjects_affected="363" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="505"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="20" subjects_affected="12" subjects_at_risk="505"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Hemolysis (e.g. immune hemolytic anemia drug-related hemolysis)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Lymphatics - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmia - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Cardiac General - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="505"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing: patients without baseline audiogram and not enrolled in a monitoring program</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Otitis middle ear (non-infectious)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Vision-blurred vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="8" subjects_affected="3" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Watery eye (epiphora tearing)</sub_title>
                <counts group_id="E1" events="23" subjects_affected="10" subjects_at_risk="505"/>
                <counts group_id="E2" events="10" subjects_affected="2" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Dental: periodontal disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="505"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Dry mouth/salivary gland (xerostomia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Dysphagia (difficulty swallowing)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Fistula, GI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Heartburn/dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI</sub_title>
                <counts group_id="E1" events="46" subjects_affected="33" subjects_at_risk="505"/>
                <counts group_id="E2" events="19" subjects_affected="13" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Ileus GI (functional obstruction of bowel i.e. neuroconstipation)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Incontinence anal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (functional/symptomatic)</sub_title>
                <counts group_id="E1" events="20" subjects_affected="12" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="505"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Perforation, GI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Rectal bleeding/hematochezia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Ulcer, GI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="505"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death not associated with CTCAE term</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Edema: trunk/genital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="5" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Extremity-lower (gait/walking)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="157" subjects_affected="90" subjects_at_risk="505"/>
                <counts group_id="E2" events="80" subjects_affected="51" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="105" subjects_affected="77" subjects_at_risk="505"/>
                <counts group_id="E2" events="64" subjects_affected="50" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Pain - Other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="505"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" events="73" subjects_affected="42" subjects_at_risk="505"/>
                <counts group_id="E2" events="67" subjects_affected="33" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Syndromes - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="56" subjects_affected="20" subjects_at_risk="505"/>
                <counts group_id="E2" events="47" subjects_affected="26" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Colitis, infectious (e.g., Clostridium difficile)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="40" subjects_affected="29" subjects_at_risk="505"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" events="23" subjects_affected="12" subjects_at_risk="505"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils</sub_title>
                <counts group_id="E1" events="61" subjects_affected="36" subjects_at_risk="505"/>
                <counts group_id="E2" events="28" subjects_affected="21" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC</sub_title>
                <counts group_id="E1" events="33" subjects_affected="25" subjects_at_risk="505"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Vessel injury-artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>AST, SGOT(serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="18" subjects_affected="12" subjects_at_risk="505"/>
                <counts group_id="E2" events="29" subjects_affected="12" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>CD4 count</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Cholesterol serum-high (hypercholesteremia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>GGT (gamma-Glutamyl transpeptidase)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>INR (International Normalized Ratio of prothrombin time)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="176" subjects_affected="56" subjects_at_risk="505"/>
                <counts group_id="E2" events="113" subjects_affected="50" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="87" subjects_affected="18" subjects_at_risk="505"/>
                <counts group_id="E2" events="90" subjects_affected="31" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other</sub_title>
                <counts group_id="E1" events="12" subjects_affected="4" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="312" subjects_affected="110" subjects_at_risk="505"/>
                <counts group_id="E2" events="252" subjects_affected="97" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>PTT (Partial Thromboplastin Time)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="19" subjects_affected="2" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" events="15" subjects_affected="4" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="14" subjects_at_risk="505"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Calcium serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="505"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Glucose serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" events="142" subjects_affected="48" subjects_at_risk="505"/>
                <counts group_id="E2" events="82" subjects_affected="40" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Magnesium serum-low (hypomagnesemia)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Pancreatic endocrine: glucose intolerance</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Phosphate serum-low (hypophosphatemia)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Potassium serum-high (hyperkalemia)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Potassium serum-low (hypokalemia)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Sodium serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="505"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis (non-septic)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy)</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="505"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Osteonecrosis (avascular necrosis)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Secondary Malignancy - possibly related to cancer treatment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia (incoordination)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Extrapyramidal/involuntary movement/restlessness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Hemorrhage CNS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Neurology - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Neuropathy: cranial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Neuropathy: motor</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="505"/>
                <counts group_id="E2" events="32" subjects_affected="17" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" events="50" subjects_affected="33" subjects_at_risk="505"/>
                <counts group_id="E2" events="67" subjects_affected="33" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="64" subjects_affected="44" subjects_at_risk="505"/>
                <counts group_id="E2" events="43" subjects_affected="34" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Pyramidal tract dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Syncope (fainting)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="505"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Taste alteration (dysgeusia)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="3" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Vasovagal episode</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Mood alteration</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Personality/behavioral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder spasms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Fistula, GU</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Hematuria (in the absence of vaginal bleeding)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Hemoglobinuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Hemorrhage GU</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Incontinence, urinary</sub_title>
                <counts group_id="E1" events="13" subjects_affected="3" subjects_at_risk="505"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Obstruction, GU</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="295" subjects_affected="89" subjects_at_risk="505"/>
                <counts group_id="E2" events="174" subjects_affected="70" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Renal/Genitourinary - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Stricture/stenosis (including anastomotic), GU</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Urinary retention (including neurogenic bladder)</sub_title>
                <counts group_id="E1" events="12" subjects_affected="5" subjects_at_risk="505"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis (including sneezing nasal stuffiness postnasal drip)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="505"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Hemorrhage pulmonary/upper respiratory</sub_title>
                <counts group_id="E1" events="603" subjects_affected="153" subjects_at_risk="505"/>
                <counts group_id="E2" events="123" subjects_affected="54" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Nasal cavity/paranasal sinus reactions</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Voice changes/dysarthria (e.g. hoarseness loss or alteration in voice laryngitis)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin - Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Hair loss/alopecia (scalp or body)</sub_title>
                <counts group_id="E1" events="17" subjects_affected="7" subjects_at_risk="505"/>
                <counts group_id="E2" events="12" subjects_affected="5" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" events="17" subjects_affected="8" subjects_at_risk="505"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Photosensitivity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="155" subjects_affected="69" subjects_at_risk="505"/>
                <counts group_id="E2" events="119" subjects_affected="56" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Rash: hand-foot skin reaction</sub_title>
                <counts group_id="E1" events="11" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Sweating (diaphoresis)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Urticaria (hives welts wheals)</sub_title>
                <counts group_id="E1" events="15" subjects_affected="10" subjects_at_risk="505"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Dermal change lymphedema phlebolymphedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Hemorrhage/Bleeding - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Hot flashes/flushes</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="505"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="568" subjects_affected="156" subjects_at_risk="505"/>
                <counts group_id="E2" events="198" subjects_affected="82" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="505"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="504"/>
              </event>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="505"/>
                <counts group_id="E2" events="61" subjects_affected="20" subjects_at_risk="504"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>William Kevin Kelly, DO</name_or_title>
      <organization>Thomas Jefferson University</organization>
      <email>wm.kevin.kelly@jefferson.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

